Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRP-S124
- Development stage
- Unknown
- Lead developer
- Kyorin Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intraduodenal
01
Overview
KRP-S124 (also known as BAY2925976) is a small molecule modulator of the alpha-2C adrenergic receptor (ADRA2C) being developed by Kyorin Pharmaceutical for the treatment of obstructive sleep apnea (OSA). Originally discovered by Bayer and licensed to Kyorin in December 2024, the compound represents a novel pharmacological approach to OSA, a condition that currently relies heavily on mechanical interventions like continuous positive airway pressure (CPAP) devices. By targeting the ADRA2C receptor, the drug is intended to modulate the neural control of upper airway muscles to prevent collapse during sleep. It is currently in early-stage clinical development.
02
Targets
ADRA2C (α2C)
Beyond the preview
Go deeper on KRP-S124.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRP-S124.